NUVESSA

PeakSM

metronidazole

NDAVAGINALGEL

Approved

Mar 2014

Lifecycle

Peak

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

[see Microbiology ( )].

Pharmacologic Class:

Nitroimidazole Antimicrobial

Indications (2)

bacterial vaginosis in females 12 years of age older

Clinical Trials (5)

NCT03830333Phase 3Completed

Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)

Started Mar 2019

268 enrolled

Complicated Intra-abdominal Infections

NCT03329092Phase 3Completed

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

Started Apr 2018

422 enrolled

Complicated Intra-abdominal InfectionHosptial Acquired PneumoniaVentilator Associated Pneumonia

NCT03217136Phase 2Completed

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

Started Apr 2018

94 enrolled

Complicated Intra-Abdominal Infection

NCT02911298Phase 1Completed

Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules

Started Nov 2016

NCT02739997Phase 3Completed

Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)

Started Apr 2016

100 enrolled

Intra-abdominal InfectionComplicated Intra-abdominal Infection